Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975 · View on ClinicalTrials.gov ↗
Study Summary
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.
Conditions Studied
Interventions
- DRUG NAV-240
- DRUG Placebo to match NAV-240
Study Locations (10)
Florida
- Accel Research Sites Network — Maitland
- Floridian Research Institute — Miami
- Cordova Research Institute — Miami
- Tory Sullivan MD PA - Dermatology — North Miami Beach
- MplusM - D&H Tamarac Research Center — Tamarac
- ForCare Clinical Research — Tampa
Arizona
- Medical Dermatology Specialist — Phoenix
Kentucky
- Kentucky Advanced Medical Research LLC — Murray
New Hampshire
- ActivMed Practices & Research, LLC — Portsmouth
New York
- Equity Medical, LLC — The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07384975
The ClinicalTrials.gov registry entry for NCT07384975 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Navigator Medicines, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions — of which NAV-240 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07384975 reports 10 study locations spanning 5 distinct geographic areas — top geographies include Florida, Arizona, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07384975 about?
NCT07384975 is a clinical study titled "A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa". The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 1...
What is the current status of trial NCT07384975?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-01-05. Estimated completion is 2027-10.
What conditions does trial NCT07384975 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07384975?
The interventions under investigation include: NAV-240 (DRUG), Placebo to match NAV-240 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07384975?
This trial is sponsored by Navigator Medicines, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07384975 being conducted?
This trial has 10 study locations across Arizona, Florida, Kentucky, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.